Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines

RECOMMENDED

Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases

Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Circ Cardiovasc Qual Outcomes

Pavlović J, Greenland P, Franco OH, Kavousi M, Ikram MK, Deckers JW, Ikram MA, Leening MJG

doi: 10.1161/CIRCOUTCOMES.120.007183

Lipid-Lowering Drugs

A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention

JAMA Cardiol.

Thanassoulis G, Sniderman AD, Pencina MJ

doi: 10.1001/jamacardio.

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs

ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study

Eur Heart J.

Mortensen MB, Nordestgaard BG, Afzal S, Falk E

doi: 10.1093/eurheartj/ehw426

RECOMMENDED

Lipid-Lowering Drugs

Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

JAMA Cardiol.

Mortensen MB, Nordestgaard BG

doi: 10.1001/jamacardio.2019.3665.

Heart, Artery and Coronary Diseases

Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement

JAMA.

US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB

doi: 10.1001/jama.2018.8359.

Thrombosis and Stroke

Screening for Asymptomatic Carotid Artery Stenosis: US Preventive Services Task Force Recommendation Statement

JAMA

US Preventive Services Task Force., Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Donahue K, Doubeni CA, Epling JW Jr, Kubik M, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB

doi: 10.1001/jama.2020.26988

Cardiac Arrest or DeathAtrial FibrillationHeart, Artery and Coronary DiseasesHeart Failure

Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Heart Rhythm.

Kusumoto FM, Bailey KR, Chaouki AS, Deshmukh AJ, Gautam S, Kim RJ, Kramer DB, Lambrakos LK, Nasser NH, Sorajja D

doi: 10.1016/j.hrthm.2017.10.037.

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease

Eur Heart J.

Mortensen MB, Nordestgaard BG

doi: 10.1093/eurheartj/ehaa150.

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering DrugsMyocardial Infarction

Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry

J Am Coll Cardiol.

Singh A, Collins BL, Gupta A, Fatima A, Qamar A, Biery D, Baez J, Cawley M, Klein J, Hainer J, Plutzky J, Cannon CP, Nasir K, Di Carli MF, Bhatt DL, Blankstein R

doi: 10.1016/j.jacc.2017.11.007.

Related content